Search

Your search keyword '"Ocampo, Christopher"' showing total 125 results
Start Over Author "Ocampo, Christopher"
125 results on '"Ocampo, Christopher"'

1. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

Author

Cleary, James M., Calvo, Emiliano, Moreno, Victor, Juric, Dejan, Shapiro, Geoffrey I., Vanderwal, Carol Ann, Hu, Beibei, Gifford, Maryella, Barch, David, Roberts-Rapp, Lisa, Ansell, Peter J., Xiong, Hao, Ocampo, Christopher, and Tolcher, Anthony W.

Published
2020
Full Text
View/download PDF

2. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

Author

Lassman, Andrew B., Aldape, Kenneth D., Ansell, Peter J., Bain, Earle, Curran, Walter J., Eoli, Marica, French, Pim J., Kinoshita, Manabu, Looman, Jim, Mehta, Minesh, Muragaki, Yoshihiro, Narita, Yoshitaka, Ocampo, Christopher, Roberts-Rapp, Lisa, Song, Minghao, Vogelbaum, Michael A., Walenkamp, Annemiek M. E., Wang, Tony J. C., Zhang, Peixin, and van den Bent, Martin J.

Published
2019
Full Text
View/download PDF

3. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase

Author

Min, Jin-Young, Ocampo, Christopher J., Stevens, Whitney W., Price, Caroline P.E., Thompson, Christopher F., Homma, Tetsuya, Huang, Julia H., Norton, James E., Suh, Lydia A., Pothoven, Kathryn L., Conley, David B., Welch, Kevin C., Shintani-Smith, Stephanie, Peters, Anju T., Grammer, Leslie C., III, Harris, Kathleen E., Hulse, Kathryn E., Kato, Atsushi, Modyanov, Nikolai N., Kern, Robert C., Schleimer, Robert P., and Tan, Bruce K.

Published
2017
Full Text
View/download PDF

8. Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease

Author

Stevens, Whitney W., Ocampo, Christopher J., Berdnikovs, Sergejs, Sakashita, Masafumi, Mahdavinia, Mahboobeh, Suh, Lydia, Takabayashi, Tetsuji, Norton, James E., Hulse, Kathryn E., Conley, David B., Chandra, Rakesh K., Tan, Bruce K., Peters, Anju T., Grammer, Leslie C., III, Kato, Atsushi, Harris, Kathleen E., Carter, Roderick G., Fujieda, Shigeharu, Kern, Robert C., and Schleimer, Robert P.

Published
2015
Full Text
View/download PDF

9. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial

Author

Narita, Yoshitaka, primary, Muragaki, Yoshihiro, additional, Kagawa, Naoki, additional, Asai, Katsunori, additional, Nagane, Motoo, additional, Matsuda, Masahide, additional, Ueki, Keisuke, additional, Kuroda, Junichiro, additional, Date, Isao, additional, Kobayashi, Hiroyuki, additional, Kumabe, Toshihiro, additional, Beppu, Takaaki, additional, Kanamori, Masayuki, additional, Kasai, Shota, additional, Nishimura, Yasuko, additional, Xiong, Hao, additional, Ocampo, Christopher, additional, Yamada, Masakazu, additional, and Mishima, Kazuhiko, additional

Published
2021
Full Text
View/download PDF

11. Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

Author

Camidge, D. Ross, primary, Moiseenko, Fedor, additional, Cicin, Irfan, additional, Horinouchi, Hidehito, additional, Filippova, Elena, additional, Bar, Jair, additional, Lu, Shun, additional, Tomasini, Pascale, additional, Ocampo, Christopher, additional, Sullivan, Danielle, additional, Maag, David, additional, and Goldman, Jonathan W., additional

Published
2021
Full Text
View/download PDF

13. Preliminary Results of Safety and PK of Telisotuzumab Vedotin (T) in Japanese Patients with Advanced Solid Tumors

Author

Murakami, Haruyasu, primary, Wakuda, Kazushige, additional, Kenmotsu, Hirotsugu, additional, Todaka, Akiko, additional, Yokota, Tomoya, additional, Yamamoto, Noboru, additional, Shimizu, Toshio, additional, Shimomura, Akihiko, additional, Yonemori, Kan, additional, Ocampo, Christopher, additional, Parikh, Apurvasena, additional, Fukasawa, Kazuteru, additional, Matsumoto, Ikiru, additional, Suzuki, Koji, additional, and Fujiwara, Yutaka, additional

Published
2019
Full Text
View/download PDF

16. Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.

Author

Narita, Yoshitaka, primary, Muragaki, Yoshihiro, additional, Maruyama, Takashi, additional, Kagawa, Naoki, additional, Asai, Katsunori, additional, Kuroda, Junichiro, additional, Kurozumi, Kazuhiko, additional, Nagane, Motoo, additional, Matsuda, Masahid, additional, Ueki, Keisuke, additional, Ocampo, Christopher Joseph, additional, Matsumoto, Ikiru, additional, Odagawa, Reiko, additional, Nishimura, Yasuko, additional, and Mishima, Kazuhiko, additional

Published
2019
Full Text
View/download PDF

19. Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.

Author

Ahluwalia, Manmeet Singh, primary, Dimino, Cara R., additional, Mansukhani, Mahesh M., additional, Murty, Vundavalli V., additional, Canoll, Peter, additional, Narita, Yoshitaka, additional, Muragaki, Yoshihiro, additional, Gan, Hui Kong, additional, Merrell, Ryan Thomas, additional, Van Den Bent, Martin J., additional, Zha, Zheng, additional, Roberts-Rapp, Lisa, additional, Jiang, Fang, additional, Guseva, Maria, additional, Bain, Earle E., additional, Ocampo, Christopher Joseph, additional, Ansell, Peter J, additional, and Lassman, Andrew B., additional

Published
2018
Full Text
View/download PDF

20. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

Author

Goss, Glenwood D., primary, Vokes, Everett E., additional, Gordon, Michael S., additional, Gandhi, Leena, additional, Papadopoulos, Kyriakos P., additional, Rasco, Drew W., additional, Fischer, JuDee S., additional, Chu, Katharine L., additional, Ames, William W., additional, Mittapalli, Rajendar K., additional, Lee, Ho-Jin, additional, Zeng, Jiewei, additional, Roberts-Rapp, Lisa A., additional, Loberg, Lise I., additional, Ansell, Peter J., additional, Reilly, Edward B., additional, Ocampo, Christopher J., additional, Holen, Kyle D., additional, and Tolcher, Anthony W., additional

Published
2018
Full Text
View/download PDF

21. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in chronic rhinosinusitis with nasal polyps: the possible role of the non-gastric H,K-ATPase

Author

Min, Jin-Young, Ocampo, Christopher J., Stevens, Whitney W., Price, Caroline P.E., Thompson, Christopher F., Homma, Tetsuya, Huang, Julia H., Norton, James E., Suh, Lydia A., Pothoven, Kathryn L., Conley, David B., Welch, Kevin C., Shintani-Smith, Stephanie, Peters, Anju T., Grammer, Leslie C., Harris, Kathleen E., Hulse, Kathryn E., Kato, Atsushi, Modyanov, Nikolai N., Kern, Robert C., Schleimer, Robert P., and Tan, Bruce K.

Subjects
Adult, Male, Imidazoles, Epithelial Cells, Proton Pump Inhibitors, Middle Aged, Nasal Lavage Fluid, Article, Cell Line, H(+)-K(+)-Exchanging ATPase, Nasal Mucosa, Young Adult, Nasal Polyps, Gene Knockdown Techniques, Chronic Disease, Cytokines, Humans, Benzimidazoles, Female, Pulmonary Eosinophilia, Sinusitis, Tomography, X-Ray Computed, Cells, Cultured, Aged, Rhinitis
Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by tissue eosinophilia that is associated with poor prognosis. Recent findings that proton pump inhibitors (PPIs) directly modulate the expression of eotaxin-3, an eosinophil chemoattractant, in patients with eosinophilic diseases suggest therapeutic potential for PPIs in those with CRSwNP.We assessed the effect of type 2 mediators, particularly IL-13 and eotaxin-3, on tissue eosinophilia and disease severity in patients with chronic rhinosinusitis (CRS). Further investigation focused on PPI suppression of eotaxin-3 expression in vivo and in vitro, with exploration of underlying mechanisms.Type 2 mediator levels in nasal tissues and secretions were measured by using a multiplex immunoassay. Eotaxin-3 and other chemokines expressed in IL-13-stimulated human sinonasal epithelial cells (HNECs) and BEAS-2B cells with or without PPIs were assessed by using ELISA, Western blotting, real-time PCR, and intracellular pH imaging.Nasal tissues and secretions from patients with CRSwNP had increased IL-13, eotaxin-2, and eotaxin-3 levels, and these were positively correlated with tissue eosinophil cationic protein levels and radiographic scores in patients with CRS (P .05). IL-13 stimulation of HNECs and BEAS-2B cells dominantly induced eotaxin-3 expression, which was significantly inhibited by PPIs (P .05). Patients with CRS taking PPIs also showed lower in vivo eotaxin-3 levels compared with those without PPIs (P .05). Using intracellular pH imaging and altering extracellular KOur results demonstrated that PPIs reduce IL-13-induced eotaxin-3 expression by airway epithelial cells. Furthermore, mechanistic studies suggest that the nongastric H,K-ATPase is necessary for IL-13-mediated epithelial responses, and its inhibitors, including PPIs, might be of therapeutic value in patients with CRSwNP by reducing epithelial production of eotaxin-3.

Published
2016

22. Abstract A028: Biomarker analysis in a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to overexpress the epidermal growth factor receptor (EGFR)

Author

Calvo, Emiliano, primary, Cleary, James M., additional, Moreno, Victor, additional, Gifford, Maryella, additional, Roberts-Rapp, Lisa, additional, Ansell, Peter J., additional, Lee, Ho-Jin, additional, Hu, Beibei, additional, Barch, David, additional, Ocampo, Christopher, additional, and Tolcher, Anthony W., additional

Published
2018
Full Text
View/download PDF

25. Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.

Author

Calvo, Emiliano, primary, Cleary, James M., additional, Moreno, Victor, additional, Gifford, Maryella, additional, Roberts-Rapp, Lisa, additional, Ansell, Peter J, additional, Mittapalli, Rajendar K., additional, Lee, Ho-Jin, additional, Hu, Beibei, additional, Barch, David, additional, Ocampo, Christopher Joseph, additional, and Tolcher, Anthony W., additional

Published
2017
Full Text
View/download PDF

27. Preservation of glucose metabolism in hypertrophic GLUT4-null hearts

Author

STENBIT, ANTINE E., KATZ, ELLEN B., CHATHAM, JOHN C., GEENEN, DAVID L., FACTOR, STEPHEN M., WEISS, ROBERT G., TSAO, TSU-SHUEN, MALHOTRA, ASHWANI, CHACKO, V. P., OCAMPO, CHRISTOPHER, JELICKS, LINDA A., and CHARRON, MAUREEN J.

Subjects
Glucose metabolism -- Protection and preservation, Hypertrophy -- Health aspects, Mice as laboratory animals -- Research, Biological sciences
Abstract

Preservation of glucose metabolism in hypertrophic GLUT4-null hearts. Am J Physiol Heart Circ Physiol 279: H313-H318, 2000.--GLUT4-null mice lacking the insulin-sensitive glucose transporter are not diabetic but do exhibit abnormalities in glucose and lipid metabolism. The most striking morphological consequence of ablating GLUT4 is cardiac hypertrophy. GLUT4-null hearts display characteristics of hypertrophy caused by hypertension. However, GLUT4-null mice have normal blood pressure and maintain a normal cardiac contractile protein profile. Unexpectedly, although they lack the predominant glucose transporter in the heart, GLUT4-null hearts transport glucose and synthesize glycogen at normal levels, but gene expression of rate-limiting enzymes involved in fatty acid oxidation is decreased. The GLUT4-null heart represents a unique model of hypertrophy that may be used to study the consequences of altered substrate utilization in normal and pathophysiological conditions. transport; glycogen; nuclear magnetic resonance

Published
2000

28. Proton Pump Inhibitors (PPIs) May Modulate More Than Just Reflux in Chronic Rhinosinusitis with Nasal Polyps

Author

Min, Jin Young, primary, Kern, Robert C., additional, Ocampo, Christopher J., additional, Stevens, Whitney W., additional, Price, Caroline P.E., additional, Thompson, Christopher F., additional, Homma, Tetsuya, additional, Conley, David B., additional, Shintani-Smith, Stephanie, additional, Huang, Julia H., additional, Suh, Lydia, additional, Norton, James E., additional, Hulse, Kathryn E., additional, Kato, Atsushi, additional, Schleimer, Robert P., additional, and Tan, Bruce K., additional

Published
2016
Full Text
View/download PDF

29. Control Banding para desechos: una matriz para la comparación rápida y simple del impacto sobre el ambiente de los desechos que contienen sustancias químicas

Author

Rodríguez Corrales, José Ángel, González Murillo, Alex Horacio, Mora Aparicio, Carmen, and Solís Ocampo, Christopher

Abstract

Diminishing the polluting effect of wastes upon citizens and the environment represents an important aim to fulfill to guarantee a better life quality and a sustainable development. To address this problem a classification system of any chemical output and a score based in the quantity and danger was obtained by a control banding technique. By developing a spreadsheet based in this concept, the entries were specified for the chemical and toxic properties of any substance with a MSDS registry. From this work, it was obtained a classification based in the quantity, concentration, known toxicity and effects (i.e. LD50 and Risk Phases, known as R phrases) inside a fixed scale for each point. This tool can be applied to several situations where chemical wastes cannot be assessed once they are eliminated. La disminución del efecto contaminante de los desechos sobre los ciudadanos y el ambiente representa un objetivo importante a alcanzar para garantizar una mejor calidad de vida y un desarrollo sostenible. Para atender este problema, se obtuvo un sistema de clasificación de los desechos químicos y un puntaje basado en la cantidad y peligro, utilizando una técnica de control por bandas (“control banding”). A través del desarrollo de una matriz basada en este concepto, se especificaron las entradas para las propiedades químicas y tóxicas de una sustancia con el registro de su MSDS. De este trabajo, se obtuvo una clasificación basada en la cantidad, concentración, toxicidad conocida y efectos (i.e. LD50 y las Frases de Riesgo, conocidas como frases R) dentro de una escala fijada para cada punto. Esta herramienta puede ser aplicada a diversas situaciones donde los desechos químicos no pueden ser valorados una vez que son eliminados.

Published
2013

31. Omeprazole Has Anti-Inflammatory Effects on Type 2 Cytokine-Stimulated Human Airway Epithelial Cells

Author

Min, Jin Young, primary, Kern, Robert C., additional, Ocampo, Christopher J., additional, Homma, Tetsuya, additional, Conley, David B., additional, Shintani-Smith, Stephanie, additional, Huang, He, additional, Suh, Lydia, additional, Norton, James E., additional, Hulse, Kathryn E., additional, Kato, Atsushi, additional, Schleimer, Robert P., additional, and Tan, Bruce K., additional

Published
2015
Full Text
View/download PDF

32. Investigation of Molecular Characteristics of Aspirin Exacerbated Respiratory Disease

Author

Stevens, Whitney W., primary, Ocampo, Christopher J., additional, Norton, James E., additional, Carter, Roderick G., additional, Suh, Lydia, additional, Grammer, Leslie C., additional, Hulse, Kathryn E., additional, Peters, Anju T., additional, Chandra, Rakesh K., additional, Conley, David B., additional, Kern, Robert C., additional, Tan, Bruce K., additional, and Schleimer, Robert P., additional

Published
2015
Full Text
View/download PDF

36. Oncostatin M Is Elevated In Chronic Rhinosinusitis and Decreases Barrier Function In Human Airway Epithelium

Author

Pothoven, Kathryn L., primary, Norton, James, additional, Ocampo, Christopher, additional, Suh, Lydia, additional, Carter, Roderick, additional, Hulse, Kathryn E., additional, Seshadri, Sudarshan, additional, Tan, Bruce K., additional, Chandra, Rakesh, additional, Peters, Anju T., additional, Harris, Kathleen E., additional, Conley, David, additional, Grammer, Leslie C., additional, Kern, Robert C., additional, and Schleimer, Robert P., additional

Published
2014
Full Text
View/download PDF

41. Levels of the Cytokines IL-5, IL-13 and Rantes in Nasal Lavage Fluids Parallel the Cytokine Content of Nasal Polyps in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Author

Ocampo, Christopher, primary, Suh, Lydia, additional, Kern, Robert, additional, Kato, Atsushi, additional, Conley, David, additional, Chandra, Rakesh, additional, Tan, Bruce, additional, Norton, James, additional, Peters, Anju, additional, Grammer, Leslie C., additional, and Schleimer, Robert P., additional

Published
2013
Full Text
View/download PDF

50. Mitochondrial calcium transporting pathways during hypoxia and reoxygenation in single rat cardiomyocytes.

Author

Griffiths, Elinor J., Ocampo, Christopher J., Savage, Jason S., Rutter, Guy A., Hansford, Richard G., Stern, Michael D., and Silverman, Howard S.

Abstract

Objective: Mitochondrial [Ca2+] ([Ca2+]m) rises in parallel with cytosolic [Ca2+] ([Ca2+]c) following ATP-depletion rigor contracture induced by hypoxia in isolated cardiomyocytes. We investigated the pathways involved in the hypoxia induced changes in [Ca2+]m by using known inhibitors of mitochondrial Ca2+ transport, namely ruthenium red, an inhibitor of the Ca2+ uniporter (the normal influx route) and clonazepam, an inhibitor of Na+/Ca2+ exchange, (the normal efflux route). Methods: [Ca2+]m was determined from indo-1/am loaded rat myocytes where the cytosolic fluorescence signal had been quenched by superfusion with Mn2+. [Ca2+]c was measured by loading myocytes with indo-1 pentapotassium salt during the isolation procedure. Cells were placed in a specially developed chamber for induction of hypoxia and reoxygenated 40 min after rigor development. Results: 50% of control cells hypercontracted upon reoxygenation; this correlated with a [Ca2+]m or [Ca2+]c higher than approximately 350 nM at the end of rigor. Clonazepam completely abolished the rigor-induced rise in [Ca2+]m but not [Ca2+]c. On reoxygenation [Ca2+]m increased over the first 5 min and remained elevated whereas [Ca2+]c fell. In the presence of ruthenium red a dramatic increase in [Ca2+]m occurred 5–10 min after rigor development (the indo-1 fluorescence signal was saturated); [Ca2+]c also increased but to a lesser extent. On reoxygenation, [Ca2+]m fell rapidly even though cells hypercontracted and [Ca2+]c remained elevated. Conclusions: During hypoxia following rigor development Ca2+ uptake into mitochondria occurs largely via the Na+/Ca2+ exchanger rather than the Ca2+ uniporter whereas on reoxygenation the transporters resume their normal directionality. [ABSTRACT FROM PUBLISHER]

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results